{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:44:59Z","timestamp":1790192699055,"version":"4.1.0"},"reference-count":66,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"KAKENHI","award":["15K10881 and 18K09424"],"award-info":[{"award-number":["15K10881 and 18K09424"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Diabetic retinopathy (DR) is one of the leading causes of blindness globally. Retinal neuronal abnormalities occur in the early stage in DR. Therefore, maintaining retinal neuronal activity in DR may prevent vision loss. Previously, pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, was suggested as a promising drug in hypertriglyceridemia. However, the role of pemafibrate remains obscure in DR. Therefore, we aimed to unravel systemic and retinal changes by pemafibrate in diabetes. Adult mice were intraperitoneally injected with streptozotocin (STZ) to induce diabetes. After STZ injection, diet supplemented with pemafibrate was given to STZ-induced diabetic mice for 12 weeks. During the experiment period, body weight and blood glucose levels were examined. Electroretinography was performed to check the retinal neural function. After sacrifice, the retina, liver, and blood samples were subjected to molecular analyses. We found pemafibrate mildly improved blood glucose level as well as lipid metabolism, boosted liver function, increased serum fibroblast growth factor21 level, restored retinal functional deficits, and increased retinal synaptophysin protein expression in STZ-induced diabetic mice. Our present data suggest a promising pemafibrate therapy for the prevention of early DR by improving systemic metabolism and protecting retinal function.<\/jats:p>","DOI":"10.3390\/ijms21176243","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T10:23:08Z","timestamp":1598610188000},"page":"6243","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Pemafibrate Protects Against Retinal Dysfunction in a Murine Model of Diabetic Retinopathy"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1013-5737","authenticated-orcid":false,"given":"Yohei","family":"Tomita","sequence":"first","affiliation":[{"name":"Laboratory of Photobiology, Keio University School of Medicine, Tokyo 160-8582, Japan"},{"name":"Department of Ophthalmology, Keio University School of Medicine, Tokyo 160-8582, Japan"},{"name":"Boston Children\u2019s Hospital\/ Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5992-9039","authenticated-orcid":false,"given":"Deokho","family":"Lee","sequence":"additional","affiliation":[{"name":"Laboratory of Photobiology, Keio University School of Medicine, Tokyo 160-8582, Japan"},{"name":"Department of Ophthalmology, Keio University School of Medicine, Tokyo 160-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5377-6772","authenticated-orcid":false,"given":"Yukihiro","family":"Miwa","sequence":"additional","affiliation":[{"name":"Laboratory of Photobiology, Keio University School of Medicine, Tokyo 160-8582, Japan"},{"name":"Department of Ophthalmology, Keio University School of Medicine, Tokyo 160-8582, Japan"},{"name":"Animal Eye Care, Tokyo Animal Eye Clinic, Tokyo 158-0093, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Laboratory of Photobiology, Keio University School of Medicine, Tokyo 160-8582, Japan"},{"name":"Department of Ophthalmology, Keio University School of Medicine, Tokyo 160-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8874-7111","authenticated-orcid":false,"given":"Masayuki","family":"Ohta","sequence":"additional","affiliation":[{"name":"Kowa Company, Ltd., Tokyo 103-8433, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5457-2720","authenticated-orcid":false,"given":"Kazuo","family":"Tsubota","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Keio University School of Medicine, Tokyo 160-8582, Japan"},{"name":"Tsubota Laboratory, Inc., Tokyo 160-0016, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihide","family":"Kurihara","sequence":"additional","affiliation":[{"name":"Laboratory of Photobiology, Keio University School of Medicine, Tokyo 160-8582, Japan"},{"name":"Department of Ophthalmology, Keio University School of Medicine, Tokyo 160-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,8,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4103\/0301-4738.100542","article-title":"The worldwide epidemic of diabetic retinopathy","volume":"60","author":"Zheng","year":"2012","journal-title":"Indian J. Ophtalmol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/s41433-018-0021-7","article-title":"Clinical pharmacology of intravitreal anti-VEGF drugs","volume":"32","author":"Fogli","year":"2018","journal-title":"Eye"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"319692","DOI":"10.1155\/2015\/319692","article-title":"Role of Electrophysiology in the Early Diagnosis and Follow-Up of Diabetic Retinopathy","volume":"2015","author":"Pescosolido","year":"2015","journal-title":"J. Diabetes Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11883-020-0823-5","article-title":"Pemafibrate, a New Selective PPAR\u03b1 Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases","volume":"22","author":"Yamashita","year":"2020","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Kusunoki, M., Natsume, Y., Oshida, Y., and Miyata, T. (2019). 615-P: A Novel Lipid-Lowering Drug Pemafibrate Enhances Effects of Statins in Serum Lipids in Japanese Patients with Type 2 Diabetes. Diabetes, 68.","DOI":"10.2337\/db19-615-P"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"754","DOI":"10.5551\/jat.28720","article-title":"Transcriptome Analysis of K-877 (a Novel Selective PPAR\u03b1 Modulator (SPPARM\u03b1))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver","volume":"22","author":"Tanaka","year":"2015","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Tomita, Y., Ozawa, N., Miwa, Y., Ishida, A., Ohta, M., Tsubota, K., and Kurihara, T. (2019). Pemafibrate Prevents Retinal Pathological Neovascularization by Increasing FGF21 Level in a Murine Oxygen-Induced Retinopathy Model. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20235878"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3389\/fphys.2019.00419","article-title":"FGF21 as Modulator of Metabolism in Health and Disease","volume":"10","author":"Tezze","year":"2019","journal-title":"Front. Physiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s12020-014-0413-9","article-title":"Basal and postprandial change in serum fibroblast growth factor-21 concentration in type 1 diabetic mellitus and in healthy controls","volume":"48","author":"Zibar","year":"2015","journal-title":"Endocrine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"E54","DOI":"10.1210\/jc.2011-1930","article-title":"Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes","volume":"97","author":"Xiao","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.toxlet.2013.02.022","article-title":"Protective effect of FGF21 on type 1 diabetes-induced testicular apoptotic cell death probably via both mitochondrial- and endoplasmic reticulum stress-dependent pathways in the mouse model","volume":"219","author":"Jiang","year":"2013","journal-title":"Toxicol. Lett."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Zhang, C., Shao, M., Yang, H., Chen, L., Yu, L., Cong, W., Tian, H., Zhang, F., Cheng, P., and Jin, L. (2013). Attenuation of hyperlipidemia- and diabetes-induced early-stage apoptosis and late-stage renal dysfunction via administration of fibroblast growth factor-21 is associated with suppression of renal inflammation. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0082275"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.freeradbiomed.2016.02.002","article-title":"Up-regulation of Nrf2 is involved in FGF21-mediated fenofibrate protection against type 1 diabetic nephropathy","volume":"93","author":"Cheng","year":"2016","journal-title":"Free Radic. Biol. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.celrep.2017.01.014","article-title":"FGF21 Administration Suppresses Retinal and Choroidal Neovascularization in Mice","volume":"18","author":"Fu","year":"2017","journal-title":"Cell Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"974","DOI":"10.2337\/db17-0830","article-title":"Fibroblast Growth Factor 21 Protects Photoreceptor Function in Type 1 Diabetic Mice","volume":"67","author":"Fu","year":"2018","journal-title":"Diabetes"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Tomita, Y., Fu, Z., Wang, Z., Cakir, B., Cho, S.S., Britton, W., Sun, Y., Hellstr\u00f6m, A., Talukdar, S., and Smith, L.E.H. (2020). Long-Acting FGF21 Inhibits Retinal Vascular Leakage in In Vivo and In Vitro Models. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21041188"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1210\/er.2017-00016","article-title":"Fibroblast Growth Factor 21-Metabolic Role in Mice and Men","volume":"38","author":"Staiger","year":"2017","journal-title":"Endocr. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Furman, B.L. (2015). Streptozotocin-Induced Diabetic Models in Mice and Rats. Curr. Protoc. Pharmacol., 70.","DOI":"10.1002\/0471141755.ph0547s70"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1350-9462(97)00005-0","article-title":"Electrical responses from diabetic retina","volume":"17","author":"Shirao","year":"1998","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10384-006-0326-0","article-title":"Changes of Oscillatory Potentials and Photopic Negative Response in Patients with Early Diabetic Retinopathy","volume":"50","author":"Kizawa","year":"2006","journal-title":"Jpn. J. Ophtalmol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1167\/iovs.03-1080","article-title":"Oscillatory potential analysis and ERGs of normal and diabetic rats","volume":"45","author":"Hancock","year":"2004","journal-title":"Investig. Ophtalmol. Vis. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1006\/exer.2002.1170","article-title":"Early retinal damage in experimental diabetes: Electroretinographical and morphological observations","volume":"74","author":"Li","year":"2002","journal-title":"Exp. Eye Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1167\/iovs.18-25372","article-title":"Longitudinal In Vivo Characterization of the Streptozotocin-Induced Diabetic Mouse Model: Focus on Early Inner Retinal Responses","volume":"60","author":"Sergeys","year":"2019","journal-title":"Investig. Ophtalmol. Vis. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1167\/iovs.11-8997","article-title":"Early neurodegeneration in the retina of type 2 diabetic patients","volume":"53","author":"Verbraak","year":"2012","journal-title":"Investig. Ophtalmol. Vis. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1167\/iovs.08-3143","article-title":"Selective loss of inner retinal layer thickness in type 1 diabetic patients with minimal diabetic retinopathy","volume":"50","author":"Kok","year":"2009","journal-title":"Investig. Ophtalmol. Vis. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7818","DOI":"10.1038\/s41598-020-64902-8","article-title":"Pemafibrate, a selective PPAR\u03b1 modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content","volume":"10","author":"Sasaki","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/toxsci\/kfj062","article-title":"The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR)","volume":"90","author":"Peraza","year":"2006","journal-title":"Toxicol. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S1350-9462(98)00006-8","article-title":"Oscillatory potentials in the retina: What do they reveal","volume":"17","author":"Wachtmeister","year":"1998","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/0042-6989(85)90214-7","article-title":"Origin of the oscillatory potentials in the primate retina","volume":"25","author":"Heynen","year":"1985","journal-title":"Vis. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF00207350","article-title":"New approaches to ophthalmic electrodiagnosis by retinal oscillatory potential, drug-induced responses from retinal pigment epithelium and cone potential","volume":"48","author":"Yonemura","year":"1979","journal-title":"Doc. Ophtalmol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"538","DOI":"10.2337\/dc17-1589","article-title":"Effects of Pemafibrate, a Novel Selective PPAR\u03b1 Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"41","author":"Araki","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jsps.2015.03.013","article-title":"Diabetes mellitus and oxidative stress-A concise review","volume":"24","author":"Asmat","year":"2016","journal-title":"Saudi Pharm. J."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Araki, M., Nakagawa, Y., Oishi, A., Han, S.-I., Wang, Y., Kumagai, K., Ohno, H., Mizunoe, Y., Iwasaki, H., and Sekiya, M. (2018). The Peroxisome Proliferator-Activated Receptor \u03b1 (PPAR\u03b1) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19072148"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"42477","DOI":"10.1038\/srep42477","article-title":"Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis","volume":"7","author":"Honda","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrendo.2016.135","article-title":"PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD","volume":"13","author":"Gross","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.molmet.2014.02.002","article-title":"Integrated physiology and systems biology of PPAR\u03b1","volume":"3","author":"Kersten","year":"2014","journal-title":"Mol. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2009.03.008","article-title":"Peroxisome proliferator-activated receptor-alpha (PPARalpha): At the crossroads of obesity, diabetes and cardiovascular disease","volume":"205","author":"Fruchart","year":"2009","journal-title":"Atherosclerosis"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1463-1326.2010.01342.x","article-title":"Therapies for diabetic dyslipidaemia","volume":"13","author":"Bell","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/dom.13686","article-title":"Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study","volume":"21","author":"Araki","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_41","first-page":"99","article-title":"Energy metabolism of the visual system","volume":"2","year":"2010","journal-title":"Eye Brain"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"8562408","DOI":"10.1155\/2019\/8562408","article-title":"Oxidative Stress as the Main Target in Diabetic Retinopathy Pathophysiology","volume":"2019","author":"Cecilia","year":"2019","journal-title":"J. Diabetes Res."},{"key":"ref_43","first-page":"66","article-title":"Quantitative assessment of the synaptophysin immuno-reactivity of the cortical neuropil in various neurodegenerative disorders with dementia","volume":"4","author":"Zhan","year":"1993","journal-title":"Dementia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1167\/iovs.02-0633","article-title":"Cone Photoreceptor Recovery after Experimental Detachment and Reattachment: An Immunocytochemical, Morphological, and Electrophysiological Study","volume":"44","author":"Sakai","year":"2003","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.1167\/iovs.06-0478","article-title":"Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, via modulating AT1R and AT2R signaling in retinal inflammation","volume":"47","author":"Kurihara","year":"2006","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.2337\/db07-1281","article-title":"Angiotensin II type 1 receptor signaling contributes to synaptophysin degradation and neuronal dysfunction in the diabetic retina","volume":"57","author":"Kurihara","year":"2008","journal-title":"Diabetes"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0306-4522(01)00345-1","article-title":"Synaptic vesicle alterations in rod photoreceptors of synaptophysin-deficient mice","volume":"107","author":"Vollrath","year":"2001","journal-title":"Neuroscience"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1021\/acs.bioconjchem.7b00588","article-title":"Design and Evaluation of Lyophilized Fibroblast Growth Factor 21 and Its Protection against Ischemia Cerebral Injury","volume":"29","author":"Yang","year":"2018","journal-title":"Bioconjugate Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.2174\/1381612825666190716101411","article-title":"Therapeutic Approaches to Alzheimer\u2019s Type of Dementia: A Focus on FGF21 Mediated Neuroprotection","volume":"25","author":"Taliyan","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1210\/me.2010-0142","article-title":"Research Resource: Comprehensive Expression Atlas of the Fibroblast Growth Factor System in Adult Mouse","volume":"24","author":"Bookout","year":"2010","journal-title":"Mol. Endocrinol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11011-015-9789-3","article-title":"Potential roles of fibroblast growth factor 21 in the brain","volume":"31","author":"Chattipakorn","year":"2016","journal-title":"Metab. Brain Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1016\/j.peptides.2007.10.007","article-title":"The fasting polypeptide FGF21 can enter brain from blood","volume":"28","author":"Hsuchou","year":"2007","journal-title":"Peptides"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1089\/neu.2017.5271","article-title":"FGF21 Protects the Blood-Brain Barrier by Upregulating PPAR\u03b3 via FGFR1\/\u03b2-klotho after Traumatic Brain Injury","volume":"35","author":"Chen","year":"2018","journal-title":"J. Neuotrauma."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/nm.3250","article-title":"FGF21 contributes to neuroendocrine control of female reproduction","volume":"19","author":"Owen","year":"2013","journal-title":"Nat. Med."},{"key":"ref_55","first-page":"1","article-title":"The Blood-Retinal Barrier in the Management of Retinal Disease: EURETINA Award Lecture","volume":"237","year":"2017","journal-title":"Ophthalmol. Int. J. Ophthalmol. Z. Augenheilkd."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.preteyeres.2013.02.001","article-title":"Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions","volume":"34","author":"Klaassen","year":"2013","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"10837","DOI":"10.1038\/s41598-020-67579-1","article-title":"PPAR\u03b1 activation directly upregulates thrombomodulin in the diabetic retina","volume":"10","author":"Shiono","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"686525","DOI":"10.1155\/2013\/686525","article-title":"Molecular Implications of the PPARs in the Diabetic Eye","volume":"2013","author":"Ciudin","year":"2013","journal-title":"PPAR Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjcard.2006.11.016","article-title":"Safety Considerations with Fibrate Therapy","volume":"99","author":"Davidson","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4103\/jrms.JRMS_772_19","article-title":"Fenofibrate-induced renal dysfunction, yes or no?","volume":"25","author":"Emami","year":"2020","journal-title":"J. Res. Med. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12933-017-0602-y","article-title":"Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia","volume":"16","author":"Fruchart","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1475-2840-12-82","article-title":"Selective peroxisome proliferator-activated receptor \u03b1 modulators (SPPARM\u03b1): The next generation of peroxisome proliferator-activated receptor \u03b1-agonists","volume":"12","author":"Fruchart","year":"2013","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.1016\/j.bmcl.2007.05.066","article-title":"Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists","volume":"17","author":"Yamazaki","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacl.2017.10.006","article-title":"Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor \u03b1 modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial","volume":"12","author":"Ishibashi","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.bbrc.2014.02.135","article-title":"Phase II enzyme induction by a carotenoid, lutein, in a PC12D neuronal cell line","volume":"446","author":"Miyake","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.neuint.2019.03.008","article-title":"Pharmacological HIF inhibition prevents retinal neovascularization with improved visual function in a murine oxygen-induced retinopathy model","volume":"128","author":"Miwa","year":"2019","journal-title":"Neurochem. Int."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/17\/6243\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:04:24Z","timestamp":1760177064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/17\/6243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,28]]},"references-count":66,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["ijms21176243"],"URL":"https:\/\/doi.org\/10.3390\/ijms21176243","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,28]]}}}